Is Disc Medicine, Inc. (IRON) Halal?

NASDAQ Healthcare United States $2.3B
✗ NOT HALAL
Confidence: 83/100
Disc Medicine, Inc. (IRON) is Not Halal under AAOIFI Standard 21. While the debt ratio of 1.3% is acceptable, the cash and interest-bearing securities ratio of 33.9% exceeds the 30% threshold. Disc Medicine, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.3%
/ 30%
33.9%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 1.3%
/ 33%
33.9%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 3.8%
/ 33%
98.1%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 1.3%
/ 33%
33.9%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 3.8%
/ 33%
98.1%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-6.01
P/B Ratio
3.1
EV/EBITDA
-6.5
EV: $1.5B
Revenue
$0
Beta
2.7
High volatility
Current Ratio
21.9

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -35.9%
Return on Assets (ROA) -22.5%

Cash Flow & Balance Sheet

Operating Cash Flow-$180M
Free Cash Flow-$181M
Total Debt$31M
Debt-to-Equity4.2
Current Ratio21.9
Total Assets$807M

Price & Trading

Last Close$62.01
50-Day MA$68.07
200-Day MA$70.03
Avg Volume700K
Beta2.7
52-Week Range
$30.82
$99.50

About Disc Medicine, Inc. (IRON)

CEO
Dr. John D. Quisel Esq., J.D., Ph.D.
Employees
155
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$2.3B
Currency
USD

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Disc Medicine, Inc. (IRON) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Disc Medicine, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Disc Medicine, Inc.'s debt ratio?

Disc Medicine, Inc.'s debt ratio is 1.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.8%.

What are Disc Medicine, Inc.'s key financial metrics?

Disc Medicine, Inc. has a market capitalization of $2.3B. Return on equity stands at -35.9%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.